G 蛋白偶联受体（GPCRs）是药物研发的重要靶点，但信号转导复杂阻碍了药物开发。研究人员探索了 GPCRs 的偏向性信号传导和细胞内调节剂，发现其在精准医学中具有潜在应用价值，有助于开发更安全有效的药物。 在生命科学和医学领域，药物研发一直是攻克 ...

在人体中，46 种趋化因子（chemokine）与 23 种 G 蛋白偶联受体（GPCR）的相互作用协调细胞迁移，但其选择性和 promiscuity 的分子机制不明。研究人员通过整合多种数据，明确了相关识别元件。这有助于设计新型免疫疗法和细胞疗法，为相关疾病治疗提供新思路。

“When Heptares formed, we chose to focus on GPCRs because we knew that targeting these receptors leads to drugs,” says Matt Barnes, president and head of R&D at Nxera Pharma. GPCRs are ...

Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced ...

SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today ...

G protein-coupled receptors (GPCRs) are among the most abundant proteins in the body, and responsible for triggering numerous and diverse signaling cascades. Signaling through the MAPK/ERK pathway is ...

(NASDA SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule ...

Addex Therapeutics partner Indivior advances GABAB positive allosteric modulator programme successfully through IND enabling studies: Geneva, Switzerland Tuesday, May 13, 2025, 15 ...